Medigus Series C Warrant
MDGSW
MDGSW was delisted on the 19th of July, 2023.
5 hedge funds and large institutions have $781K invested in Medigus Series C Warrant in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 1 closing their positions.
17% less funds holding
Funds holding: 6 → 5 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $67.8K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Equitec Specialists
Chicago,
Illinois
|
-$65K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2.75K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$15 |
MDGSW Hedge Fund Activity: Q2 2021 in Review
5 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Medigus Series C Warrant (MDGSW) for Q2 2021, worth a combined $781K — down 40% from $1.3M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of MDGSW and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.
The largest seller was Equitec Specialists, exiting entirely with an estimated $65K sold.
- 5 institutional investors held Medigus Series C Warrant (MDGSW) as of Q2 2021, down from 6 in Q1 2021.
- Funds reported $781K of Medigus Series C Warrant stock for Q2 2021, down 40% quarter-over-quarter.
- 0 funds opened new Medigus Series C Warrant positions in Q2 2021 and 1 closed out, a net change of -1 holder.
- The largest Medigus Series C Warrant seller in Q2 2021 was Equitec Specialists, an estimated $65K sold.
Based on aggregated 13F filings for Q2 2021.